Page 19 - Noble-Virtual-Healthcare-2024

Citius Pharmaceuticals, Inc.

SELECTED FINANCIAL ITEMS CTXR

(in millions of USD)
CQ1 '23 CQ2 '23 CQ3 '23 CQ4 '23 LTM
Income Statement Key Items
Total Revenue NA NA NA NA 0.00
Gross Profit NA NA NA NA 0.00
Gross Margin NM NM NM NM NM
EBIT (10.69) (8.67) (10.12) (9.34) (38.82)
EBIT Margin NM NM NM NM NM
Net Income to Common Shareholders (10.53) (8.48) (9.94) (9.23) (38.18)
Net Margin NM NM NM NM NM

Balance Sheet Key Items
Total Assets 104.24 110.40 103.61 97.40 97.40
Cash & Short Term Investments 29.07 33.28 26.48 20.35 20.35
% of Assets 28% 30% 26% 21% 21%
Current Assets -Total 34.90 41.11 34.37 28.21 28.21
% of Assets 33% 37% 33% 29% 29%
Total Liabilities 12.43 12.10 12.18 12.07 12.07
% of Assets 12% 11% 12% 12% 12%
Current Liabilities - Total 6.21 5.79 5.78 5.58 5.58
% of Assets 6% 5% 6% 6% 6%
Long Term Debt NA NA NA NA NA
% of Assets NM NM NM NM NM
Total Equity 91.81 98.30 91.43 85.33 85.33
% of Assets 88% 89% 88% 88% 88%

Cash Flow Statement Key Items
Net Cash Flow - Operating Activities (7.85) (9.58) (6.80) (6.14) (30.37)
Net Cash Flow - Investing NA NA NA NA 0.00
Net Cash Flow - Financing 0.03 13.80 (0.00) NA 13.83

Source: Capital IQ

PRICE / VOLUME

Source: Channelchek/QuoteMedia

Noble Capital Markets' Nineteenth Annual Small & Microcap Investor Conference